Treatment and course of a man with systemic sclerosis before and after hematopoetic blood stem cell transplantation;Therapie und Verlauf bei einem Patienten mit systemischer Sklerose vor und nach Blutstammzelltransplantation

Deutsche Medizinische Wochenschrift

Volumn 138, Issue 37, 2013, Pages 1824-1827

  Blank, N ^a   Lorenz, H M ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

alveolitis; autologous blood stem cell transplantation; highdose chemotherapy; melphalan; pulmonary fibrosis; systemic sclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; LACTATE DEHYDROGENASE; MELPHALAN; MYCOPHENOLIC ACID; SCL 70 ANTIBODY;

AGED; ARTICLE; CASE REPORT; CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG TREATMENT FAILURE; DYSPNEA; EXERCISE; HAND PAIN; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTERSTITIAL PNEUMONIA; JOINT MOBILITY; LIMB SWELLING; LUNG FIBROSIS; MAINTENANCE THERAPY; MALE; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; RIGIDITY; SCLERODERMA; STRENGTH; SYSTEMIC SCLEROSIS; WEIGHT REDUCTION;

AGED; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MELPHALAN; MYELOABLATIVE AGONISTS; PREMEDICATION; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 84883542634     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0033-1349503     Document Type: Article

References (16)

1. Burt R. K., Shah S. J., Dill K. et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet: 2011; 378 498 506
2. Elhai M., Meune C., Avouac J. et al. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology: 2012; 51 1017 1026
3. Farge D., Passweg J., van Laar J. M. et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis: 2004; 63 974 981 (Pubitemid 38961924)
4. Fransen J., Popa-Diaconu D., Hesselstrand R. et al. Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann Rheum Dis: 2011; 70 1788 1792
5. Henes J. C., Schmalzing M., Vogel W. et al. Optimization of autologous stem cell transplantation for systemic sclerosis - a single-center longterm experience in 26 patients with severe organ manifestations. J Rheumatol: 2012; 39 269 275
6. Hiepe F., Dörner T., Hauser A. E. et al. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol: 2011; 7 170 178
7. Hunzelmann N., Krieg T. Kooperationspartner der DNSS [The German network for systemic sclerosis (DNSS): current data on diagnostics and therapy]. Hautarzt: 2012; 63 01 71 75
8. Maurer B., Hensel M., Max R. et al. Autologous haematopoietic stem cell transplantation for Behcet's disease with pulmonary involvement: analysis after 5 years of follow up. Ann Rheum Dis: 2006; 65 127 129 (Pubitemid 41815655)
9. Meier F. M., Frommer K. W., Dinser R. et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis: 2012; 71 1355 1360
10. Naraghi K., van Laar J. M. Update on stem cell transplantation for systemic sclerosis: recent trial results. Curr Rheumatol Rep: 2013; 15 326
11. Nash R. A., McSweeney P. A., Crofford L. J. et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosisy. Blood: 2007; 110 1388 1396 (Pubitemid 47281441)
12. Steen V. D., Medsger T. A. Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum: 1998; 41 1613 1619 (Pubitemid 28459919)
13. Tashkin D. P., Elashoff R., Clements P. J. et al. Scleroderma Lung Study Research Group Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med: 2006; 354 2655 2666
14. Tochimoto A., Kawaguchi Y., Hara M. et al. Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up. Mod Rheumatol: 2011; 21 296 301
15. Vonk M. C., Marjanovic Z., van den Hoogen F. H. et al. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis: 2008; 67 98 104
16. Wanchu A., Suryanaryana B. S., Sharma S. et al. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study. Int J Rheum Dis: 2009; 12 239 242